We describe a new "saridwich"-type non-isotopic immunoassay for human somatotropin (GH, growth hormone) in serum.
. Growth in children depends on the regularity and amplitude of pulses of Gil secreted by the pituitary. Measurement of Gil in serum is important in the investigation of growth abnormalities in children (3, 4) and for the diagnosis of acromegaly in adults (5) . Because Gil is secreted in pulsatile fashion, it is usually measured in serum of patients with possible deficiency after stimulation by one or more of the following: exercise, insulin-induced hypoglycemia, infusion with L-dopa/propranolol or arginine; or it is measured at frequent intervals during sleep (3, 4, 6) . Measurement of Gil in urine (7) avoids the need 1 CyberFluor Inc., 179 John St., Toronto, M5T 1X4, Canada.
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4Department of Clinical Biochemistry, Mount Sinai Hospital, for blood sampling, but is unreliable in children with renal disease (8) . Suppression testing for diagnosing acromegaly or cerebral gigantism is usually done by glucose challenge (5) .
In early sensitive double-antibody radioimmunoassays for GH quantification in serum, polyclonal antibodies were used (9). Although such methods are still in use, more sensitive and specific assays based on the immunometric principle are becoming more widely adopted and are more precise (10) (11) (12) . Monoclonal antibodies are now being used in many two-site "sandwich type" configurations (10, 11, 13) . The development of nomsotopic techniques has eliminated the hazards associated with the use of radiolabeled tracers, and allows use of reagents with longer shelf-lives. The outcome has been the introduction of a new generation of nonisotopic immunoassays for Gil in serum or urine, with detection systems that incorporate enzyme, luminescent, or fluorescent probes as labels (14, 15) . A particlecounting immunoassay of human Gil has also been described (16) . Fluorescent europium complexes are useful as alternative labels to radioisotopic compounds in immunoassays.
Europium has a long fluorescence decay time, a sharp emission band, and a large Stokes shift. Fluorescence from europium complexes can be detected with very high sensitivity and low background signal by time-resolved fluorometry (17, 18) .
ilere we present a fluorescence immunoassay for GH in serum. The assay, based on the "sandwich" principle, is performed in microtiter wells coated with a monoclonal antibody to Gil. Biotin-labeled monoclonal antibody is used for detection. The degree of binding of the biotinylated antibody to captured GH molecules is determined by a bridge reaction with a europium-saturated chelate, 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA), covalently attached to streptavidin. The fluorescence of the final complex formed (antibody1-Gilantibody2-biotin-streptavidin-BcPDA-Eu3) is then quantified in the dried solid phase by pulsed fluorescence measurements with a gated fluorometer/analyzer.
To evaluate the assay clinically, we used it for testing GH in 69 patients who were being evaluated for possible GH deficiency and in one patient with acromegaly. 
Subjects and Methods

Instrumentation
Samples and Patients
Human serum samples were stored at -20 #{176}C for no longer than two months until assay.
Control subjects. Samples were taken from 59 apparently healthy nonfasting individuals, ages 20-45 years (28 men and 31 women).
Patients under investigation for possible GH deficiency. This group of 69 patients was evaluated for possible GH deficiency. Residual samples left over from routine testing were used for the method evaluation.
The case records were reviewed and the patients were grouped as follows (number of patients in parentheses): growth hormone deficiency (7); constitutional short stature, with or without delayed puberty (24); f3-thalassemia (12); Turner's syndrome (9); cancer with or without radiation treatment (5); other chronic diseases (7: three renal, two gastrointestinal, and two anemia); and miscellaneous (5: one Down's syndrome; one mental retardation; one ketotic hypoglycemia; one "MELAS" syndrome, with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; and one neurofibromatosis).
The patients all had multiple samples taken during sleep, after exercise, or during stimulatory test procedures with infusion of arginine, insulin, or L-dopalpropranolol.
Another group of 29 patients-whose diagnoses were unknown to us, whose stimulatory tests were incomplete, or from whom single or multiple samples had been drawn either during spontaneous hypoglycemia or without any specific stimulus-provided 130 additional samples that we used in the correlation studies. Acromegalic patient. A 69-year-old man had been diagnosed as acromegalic 20 years previously, based on clinical, radiological, and laboratory findings. He had refused surgical treatment and was admitted on this occasion for complications of his acromegaly (diabetes and spinal stenosis). The presence of a right pituitary adenoma was confirmed by computer tomographic scan and magnetic resonance imaging. As part of the patient's re-evaluation, he underwent a thyroliberin (thyrotropin-releasing hormone) stimulation test, an oral glucose tolerance test, and a gonadoliberin (gonadotropin-releasing hormone) stimulation test, all performed according to standard procedures.
Control sera. Lyphocheck immunoassay control serum (human), Levels I, H, and III, were from Bio-Rad Clinical Division, Richmond, CA 94801.
Procedures
Preparative procedures. The biotinylation procedure was as previously described (19) . After dialysis, we tested the biotinylated antibody at various dilutions to determine the optimal concentration for the assay. Routinely, the stock preparation, stored at 4#{176}C, is diluted in the assay buffer just before use to give a working biotinylated antibody solution of 2 g/mL.
A streptavidin-bovine thyroglobulin-BCPDA conjugate was synthesized, diluted in a Eu8-contaming buffer, and used as described elsewhere (20, 21) . Antibody-coated microtiter wells were prepared as previously reported (19) , each well being coated with 500 ng of antibody in 100 pL.
Immunoassay procedure.
Add, in duplicate, 75 L of assay buffer; 25 L of standards, controls, or patients' samples; and 50 L of the biotinylated antibody working solution to the antibody-coated wells. (Add the antibody strip by strip after the serum had been added to all 12 wells in each strip, to minimize intra-plate drift.) When the plate has been processed, cover it, shake it for 4 mm in an automated shaking device, and incubate it at 37#{176}C for 3 h. Other methods. Samples were assayed at the Hospital for Sick Children by our in-house RIA method (22) . A commercially available immunoradiometric procedure (Allegro hGH; Nichols Institute, San Juan Capistrano, CA 92675) was also used as a comparative method. (These kits incorporated the recently introduced standards in human serum instead of the previously used equine-serum-based standards.)
Results
Detection limit and dynamic range of the assay. stock GH preparation in GH-free human serum rather than in horse serum. Recoveries were 106.0 ± 8.6% with calibrators in Gil-free human serum and 85.3 ± 4.18% with calibrators in horse serum. Additionally, we compared the fluorescence values of standard curves, using standards prepared in either Gil-free human serum or horse serum. We found that the horse-serum-based standards gave -17% higher fluorescence readings at Gil concentrations from 1.5 to 50 zg/L. Possible reasons for this matrix effect are discussed later.
Cross-reactivity. Table 3 shows the cross-reactivity of the assay, expressed as the ratio of the GH equivalent concentration resulting from the cross-reacting hormone over the concentration of the hormone that produced the crossreactivity, expressed as a percentage. Cross-reactivity with other peptide hormones is negligible.
Correlation with a radioimmunoassay procedure. with the zero standard and assayed. As shown in Table 2 for three representative samples, the concentration of GH decreased linearly with increasing dilution. The correlation between the expected and observed values was excellent in all 10 cases.
GH was
Analytical recovery experiments were performed in several ways. We prepared a stock Gil preparation in horse serum, 100 .tg/L, and supplemented serum samples with either 10 or 20 zg of GH per liter. We then calculated recoveries (mean ± SD), using standard curves prepared with standards in either horse serum or GH-free human serum. The recoveries were 99.6 ± 4.2% vs standards in horse serum, and 116.8 ± 4.9% vs standards in GH-free human serum. In a similar experiment we useda 100 1tgfL
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--r Gil-deficient patients to achieve an acceptable peak value may represent physiological variation in individual response to the stimulation or impaired secretion because of their disease. In such individuals, further testing or careful measurement of growth rate would be indicated. Some of the cancer patients had received chemotherapy or radiation to the head and neck, and this most probably affected their Gil responses.
DIscussIon
The time-resolved fluorescence immunoassay procedure described here is characterized by the following principal advantages in comparison with existing techniques. It has short incubation times, and assay of a batch of 100 samples may be completed in 5 h. It requires only 50 .L of sample per duplicate assay, making it suitable for use in pediatrics. It is highly sensitive, with a detection limit s0.1 p.g/L, and it gives much higher fluorescence counts than those of an alternative time-resolved fluorescence procedure for Gil that is potentially vulnerable to contamination with europium (15) . Radioisotopes are not used and the reagents are stable for at least six months. The general performance characteristics of the assay are similar to those of existing techniques (12) . The precision is satisfactory, and accuracy indices (recovery, comparisons, linearity) show good performance. The hook effect (24) does not exist for at least up to 1000 j.g/L. Cross-reactivity with other pituitary hormones is very low ( Table 3) . The assay appears to be clinically relevant in children under investigation for Gil deficiency and in the single case of Gil excess. Because different forms of Gil are found in some acromegalic sera (25) , patients should be studied further before concluding that the assay will be suitable for all patients with this condition.
Pituitary GH consists of several distinct molecular forms that can be separated by gel filtration chromatography (26, 27) . At least three monomeric variants and several oligomere (up to a pentameric aggregate) circulate in blood (28) . The major monomeric form has a relative molecular mass of 22 000 and comprises about 73% to 77% of the total monomeric Gil (28) . In this study, we did not try to calculate the relative immunoreactivities of monomeric and polymeric forms of Gil.
Reports in the literature confirm that commercially available kits for Gil in serum produce results with large discrepancies in absolute values (29) (30) (31) . This observation makes interpretation of results between laboratories difficult when different kits are used (32) . Possible reasons for the discrepancy are differences in the primary calibration materials, the standards matrix (29, 31) , or the specificity of antibodies. The structures of the rabbit and human Gil receptors have recently been determined (33, 34) . Some workers think that the extracellular domains of the receptor molecules are released from cells into the circulation and may be the source of a Gil-binding protein in serum (35) . Others consider the receptor and binding proteins to be different cleavage products of a single m-RNA transcript in both the rat (36) and the mouse (37) . A variable fraction of the total serum GH is bound to these binding proteins [26-59%, depending on the GH isoform, with lesser proportions bound at serum Gil >20 pg/L (38) ]. The serum GH-binding protein activity increases during childhood (39) . It has yet to be determined whether these newly-described binding proteins have any possible interfering effects on GH immunoassays. However, during recovery experiments, we obmined different results depending upon whether we used horse serum or GH-free serum as the matrix of both the stock and the calibration solutions. We observed higher fluorescence readings with horse serum as the matrix, suggesting that either (a) Gil in human serum normally is partly bound to some serum component(s), such as protein(s), and the bound fraction is not fully available to the antibodies used, or (b) human serum has available Gilbinding activity so that, when supplemented with Gil, some of the hormone binds. An alternative explanation would be that a component of horse serum releases GH from a bound or aggregated form in the reference preparation and makes an additional 10-15% available for binding. The matrix effect that we observed is much less significant than that observed with a commercial immtmoradiometric assay (29) . That kit gave 2.7 times greater results than both a reference immunoassay and an alternative immunoradiometric assay when it incorporated standards in horse serum. It is apparent that these types of matrix effect are very dependent upon the epitopes recognized by the monoclonal antibodies.
Recent advances in site-directed mutagenesis have shown the specific amino acid residues and epitopes that are important for Gil binding to its receptor (40) and to several monoclonal antibodies (41) . Others have determined which parts of the GH molecule are most antigenic, without regard to bioactivity (42) . Future studies may ultimately lead to the production of monoclonal antibodies directed against functional (or bioactive) epitopes on the Gil molecule, similar to those produced against lutropin (43) . International agreement on which epitopes are most relevant to receptor binding or bioactivity-and therefore which antibodies are preferable for immunoassays-could lead to improved standardization of immunoassays for Gil. Until then, the assay described here and similar ones will continue to provide clinically useful information on patients with disorders of Gil secretion.
It is likely that the number of Gil tests performed in clinical laboratories will increase in future years. Gil produced biosynthetically by recombinant DNA technology is becoming more readily available. It is currently being tested on various groups of short children who are not overtly Gil deficient, and the debate as to who should receive Gil is ongoing (4, 44). Also there is increased emphasis on Gil measurement during sleep, a physiological stimulus, rather than after pharmacological infusion of argiine or insulin. Because of the variability of Gil release during sleep (6), samples are usually taken at 15-to 30-mm intervals during the night via an indwelling catheter, and this protocol generates six to 12 times as many samples as are taken in the course of alternative forms of testing.
